摘要
目的 观察生物制剂治疗风湿免疫性疾病患者的临床疗效.方法 选取运城市中心医院治疗的风湿免疫病患者70例作为研究对象,采用数字随机法将患者分为两组,对照组行常规治疗,观察组在对照组基础上选取生物制剂治疗,行视觉模拟评分（VAS）和生活质量评分（QOL）,观察C-反应蛋白（CRP）、血沉（ESR）变化情况,并评估临床疗效.结果 观察组治疗有效率为91.43％,显著高于对照组的71.43％,差异有统计学意义（P＜0.05）.观察组治疗后发热、疼痛、肌肉乏力、皮疹等评分分别为（0.95±0.52）、（0.87±0.44）、（1.05±0.26）、（0.93±0.18）分,均显著低于对照组,差异有统计学意义（P＜0.05）.观察组治疗后CRP水平为（9.46±7.51） mg/L,明显低于对照组,差异有统计学意义（P＜0.05）.结论 在抗风湿基础上辅以生物制剂治疗风湿免疫病,可降低CRP、ESR水平,提高临床疗效.
Objective To observe the clinical effects of biologics on self-immunity rheumatism.Methods Seventy patients with self-immunity rheumatism were randomly divided into the test group and the control group.The control group were given routine therapy and the test group were treated with biologics based on control group.QOL and VAS were graded and the changes of CRP, ESR were observed.Results The response rate of test group （91.43%） were significantly higher than that of control group （71.43%, P 〈0.05）.The scores of fever（0.95 ±0.52）, pain（0.87 ±0.44）, muscle weakness （1.05 ± 0.26）and skin rash（0.93±0.18） were significantly lower than those of control group （P 〈0.05）.The CRP level of test group [（9.46 ± 7.51） mg/L] was significantly lower than that of control group （P 〈 0.05）.Conclusions Biologics combined with general anti-rheumatism therapy can decrease CPR level and improve the clinical effects on self-immunity rheumatism.
出处
《中国实用医刊》
2015年第24期48-49,共2页
Chinese Journal of Practical Medicine
